Femasys (NASDAQ:FEMY) Stock Price Down 3.2% – Time to Sell?

Femasys Inc. (NASDAQ:FEMY)’s share price was down 3.2% on Monday . The stock traded as low as $1.17 and last traded at $1.20. Approximately 85,253 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 237,423 shares. The stock had previously closed at $1.24.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Femasys in a research report on Friday, March 28th.

Femasys Price Performance

The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The firm’s fifty day moving average price is $1.41 and its 200-day moving average price is $1.23. The stock has a market cap of $32.58 million, a P/E ratio of -1.48 and a beta of -2.55.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $1.66 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. Analysts forecast that Femasys Inc. will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Femasys in the 4th quarter worth approximately $25,000. Jane Street Group LLC purchased a new stake in Femasys in the fourth quarter worth $30,000. XTX Topco Ltd boosted its holdings in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares in the last quarter. Citadel Advisors LLC purchased a new position in Femasys during the 4th quarter valued at $45,000. Finally, Northern Trust Corp raised its holdings in Femasys by 42.6% in the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares in the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.